Novartis AG Set to Acquire Regulus Therapeutics in a Groundbreaking $1.7 Billion Deal
Novartis AG announces a strategic acquisition of Regulus Therapeutics Inc. for up to $1.7 billion, aiming to bring innovative treatments like farabursen to patients with ADPKD. The...
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 